Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868301 | 1.00 | GAA (0.38) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3337845 | 0.98 | GAA (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4542347 | 0.98 | GAA (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| SCHEMBL6568409 | 0.98 | GAA (0.39) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4248410 | 0.80 | HSP90AA1 (0.40) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL175377 | 0.79 | POLB (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4542337 | 0.79 | POLB (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Iodide SCHEMBL2464728 | 0.79 | POLB (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Bromide SCHEMBL2467102 | 0.79 | POLB (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2064723 | 0.79 | POLB (0.37) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101172952-B | Integrate chemical processes for industrial utilization of seed oils | DOW GLOBAL TECHNOLOGIES INC | 2013-03-27 | — | — | CN | claimed |
| CN-101172952-A | Integrate chemical processes for industrial utilization of seed oils | DOW GLOBAL TECHNOLOGIES INC (US) | 2008-05-07 | — | — | CN | claimed |
| CN-1649822-A | Integrated chemical process for industrial application of seed oil | DOW GLOBAL TECHNOLOGIES INC (US) | 2005-08-03 | — | — | CN | claimed |
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20220127491-A1 | COATING COMPOSITIONS | ExxonMobil Product Solutions Company | 2022-04-28 | — | — | US | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3894163-A1 | COATING COMPOSITIONS | Materia, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-10-14 | — | — | US | disclosed |
| CN-1968698-A | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE SAN DIEGO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| CN-1935855-A | Degradation of nitrile rubbers by metathesis reactions using catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-28 | — | — | CN | disclosed |
| CN-1809568-A | Pyrid (2, 1-a) - isoquinoline derivatives as dpp-iv inhibitors | HOFFMANN LA ROCHE (CH) | 2006-07-26 | — | — | CN | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
| CN-1774421-A | Process for preparing 5-(4- fluorophenyl)- 1-[2r, 4r) -4-hydroxy-6-oxo- tetrahydro-pyran -2-yl) ethyl]-2 -isopropyl -4-phenyl- 1h-pyrrole-3 -carboxylic acid phenylamide | WARNER LAMBERT CO (US) | 2006-05-17 | — | — | CN | disclosed |
| CN-1726033-A | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | PHARMACIA & UPJOHN CO LLC (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1649822-A | Integrated chemical process for industrial application of seed oil | DOW GLOBAL TECHNOLOGIES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1197076-A | Steroids having contraceptive and anti-osteoporotic activity | AKZO NOBEL NV (NL) | 1998-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | GAA 644/4885POLB 4076/4885TRPM8 3252/4885 |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | GAA 2051/4885POLB 1526/4885TRPM8 769/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | GAA 487/4885POLB 935/4885TRPM8 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.